Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 7/20 | 0.34 |
| ▸ | KRAS | P01116 | 6/20 | 0.34 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473657 | 0.81 | TSHR (0.46) | TSHRMAPK1NR2E1IDO1CES2 | |
| SCHEMBL3558744 | 0.79 | NOTUM (0.38) | TSHRMAPK1PNMTSOS1KRAS | |
| SCHEMBL21916355 | 0.72 | GABRA1 (0.34) | TSHRPNMTIDO1TDO2CES2 | |
| SCHEMBL12676168 | 0.72 | SOS1 (0.44) | TSHRMAPK1PNMTSOS1KRAS | |
| SCHEMBL3552852 | 0.71 | RXRA (0.39) | TSHRMAPK1NR2E1IDO1 | |
| SCHEMBL12587301 | 0.71 | SOS1 (0.43) | TSHRMAPK1PNMTSOS1KRAS | |
| SCHEMBL30006316 | 0.71 | SOS1 (0.43) | TSHRMAPK1PNMTSOS1KRAS | |
| SCHEMBL20327218 | 0.71 | SOS1 (0.43) | TSHRMAPK1PNMTSOS1KRAS | |
| SCHEMBL394717 | 0.70 | TSHR (0.56) | TSHRMAPK1NR2E1IDO1CES2 | |
| SCHEMBL130383 | 0.70 | TSHR (0.56) | TSHRMAPK1NR2E1IDO1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | TSHR 3505/4885MAPK1 2498/4885PNMT 4608/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | TSHR 3505/4885MAPK1 2498/4885PNMT 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.